The other successful approach of enhancing antitumor immunity against melanoma included the administration of a mAb (ipilimumab) which blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to potentiate an antitumor T-cell response (77). Here, CTLA4 is linked to melanoma.